Core Viewpoint - Psyence Biomedical Ltd. has successfully closed a private placement, raising approximately $2.0 million to support its operations and development of psilocybin-based psychedelic medicines for mental health disorders [7][8]. Company Overview - Psyence Biomedical Ltd. is the first life science biotechnology company focused on developing nature-derived psilocybin-based psychedelic medicines, listed on Nasdaq [3]. - The company aims to address unmet needs in mental health care, particularly in palliative care, through evidence-based innovation [3]. Financial Details - The private placement involved the sale of 1,000,000 common shares at a price of $2.00 per share, along with series A and series B common warrants [7]. - The gross proceeds from the offering were approximately $2.0 million, which will be used for working capital and general corporate purposes [8]. Securities Offering - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws [13]. - The company has agreed to file a resale registration statement covering the securities as part of a registration rights agreement with investors [13].

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant ...

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheetNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements. As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, ...

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to implement patient recruitment and retention strategies NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psiloc ...

Company Overview - CVS Health (NYSE: CVS) has experienced a significant stock price decline to $49 due to concerns over PBM (Pharmacy Benefit Manager) reform following an FTC lawsuit alleging abusive practices such as rebate retention and price manipulation [1] - PBMs contribute nearly half of CVS's operating income, making the company highly sensitive to regulatory changes in this area [1] Industry and Regulatory Impact - The FTC lawsuit has raised fears about potential reforms in the PBM industry, which could significantly impact CVS's profitability given its heavy reliance on PBM operations [1] Analyst Background - Yiannis Zourmpanos, founder of Yiazou IQ, is an experienced analyst with a background in auditing and consulting at Deloitte and KPMG [1] - Zourmpanos holds professional qualifications including Chartered Certified Accountant and Fellow Member of ACCA Global, with BSc and MSc degrees from UK business schools [1] - The analyst's investment style focuses on GARP/Value stocks, prioritizing high-quality businesses with strong moats and growth potential, trading at a discount to intrinsic value with a margin of safety [1] - The investment approach emphasizes long-term wealth accumulation (5-7 years) through compounding, downside protection, and sometimes taking contrarian views during market uncertainties [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Table of Contents (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR Commission File Number: 001-41937 Psyence Biomedical Ltd. | --- | --- | --- | |----- ...

Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Primary Standard Industrial Classification Code Number) 121 Richmond Street West Penthouse Suite 1300 (I.R.S. Employer Identification Number) Toronto, Ontario MK5 2K1 Telephone: + 1 (416) 346-7764 (Address, including zip code, and telephone ...

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) 121 Ric ...

Table of Contents As filed with the Securities and Exchange Commission on April 17, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) 121 ...

Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. 333- (State or Other Jurisdiction of Incorporation or Organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 21 Richmond Street West Penthouse Suite 1 ...